Corrigendum to “Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up”: [Annals of Oncology 29 suppl. 4 (2018) v238–iv255](S0923753419317119)(10.1093/annonc/mdy308)

ESMO Guidelines Committee

Research output: Contribution to journalComment/debate

2 Scopus citations

Abstract

The authors regret that in the original publication there was an error in the Staging and risk assessment section. The ESMO Guidelines Committee would like to publish a correction to this section. The original text: Survival without therapy is >5 years for stage 0 and A, >2.5 years for stage B, >1 year for stage C and ∼3 months for stage D [51]. should read as follows: Survival with therapy is >5 years for stage 0 and A, >2.5 years for stage B, >1 year for stage C and ∼3 months for stage D [51]. The authors would like to apologise for any inconvenience caused.

Original languageEnglish
Pages (from-to)666
Number of pages1
JournalAnnals of Oncology
Volume33
Issue number6
DOIs
StatePublished - Jun 2022

Fingerprint

Dive into the research topics of 'Corrigendum to “Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up”: [Annals of Oncology 29 suppl. 4 (2018) v238–iv255](S0923753419317119)(10.1093/annonc/mdy308)'. Together they form a unique fingerprint.

Cite this